BRTXQ Winning The Race To Restore
Houston, Sep 15, 2020 (Issuewire.com) - Knowing that BioRestorative Therapies Inc (BRTXQ) owns several very unique international Stem Cell patents that will be extremely valuable in the future, shareholders around the world are encouraged to hold onto their belief in this company.
The new hype of BRTXQ has gained over 1800 reactions on the Yahoo Finance chat board. BRTXQ on Yahoo
The ticker (BRTXQ) has also been a very popular topic on Reddit's penny stock community with over 298K members.
Join the Reddit Penny Stock group.
Shareholders have remained to increase their buying of BRXTQ even during uncertain times.
That information can easily be viewed on Invest Hub by clicking here.
Google Trends also shows current keyword research data that looks very promising for the company. BRTXQ has been trending upward on Google Trends for the past 3 months in both the USA & Canada.
Many very well known Twitter handles are also holding hundreds of thousands of shares of BRXTQ. Including but not limited to:
@HDOGTX, @OCMillionaire, @AlanPortell, @NickPeist, @BullPennyTrader, @pennystokgurus, @Alech789
Shareholders are patiently anticipating the loss of the "Q" on the BRXTQ ticker. This ticker change will further the credibility of the future for BioRestorative Therapies Inc. The loss of the Q typically refers to the company being back in good standing with their bankruptcy reorganization plan. Also, keeping a positive edge on the stock as the K-8 filing is supposed to be filed with the SEC sometime tomorrow 9/16/2020.
When a significant event occurs at a publicly traded company, federal law requires the firm to disclose this information to investors in a securities filing known as a Form 8-K. But the firm need not disclose immediately; instead, SEC rules give companies four business days after the event occurs within which to file an 8-K.
Filing a Form 8-K will often impact a company's stock. Which way the stock moves will depend on the nature of the news being disclosed.
Shareholders currently are anticipating a fantastic run for BRTXQ since Auctus recently joined them for help with additional working capital. This information can all be found within the recent case documents on the pacer website.
BRTXQ Pacer: https://www.pacermonitor.com/public/case/33077659/BioRestorative_Therapies,_Inc
Recently, an independent firm estimated the BRTXQ patents to be worth between the value of $50-100 million dollars.
All eyes will definitely be on BRTXQ bright and early tomorrow morning. Shareholders are highly anticipating the company to follow through with their legal obligations.
The closing stock price of BRTXQ as of today 9/15/2020 was $0.0209. With a days range from $0.0192-0.0251.
52 Week High: $0.33
Last 8-K filing per SEC government website: 4/28/2020
The future is looking great for this company to help individuals with chronic back pain and metabolic disorders.
a) 31 million back pain sufferers in the U.S.:
Estimated back pain suffers in Europe, 70 million. No direct link information was available on this. (b) Europe has 2.25 times the population of the U.S. (c) (d) They are also on median age 5 years older than the U.S. Population. This means a higher percentage of back problems as age equals health issues. Keeping the percentage equal with the U.S. Population, they would have 70 million suffering from lower back pain issues.
(b) Europe's Population:
(c) U.S. Median Age:
(d) Europe's Median Age
(e) Cost of a Microdiscectomy around $20K
https://www.drkushwaha.com/education/much-back-surgery-cost/ NOTE: 2016 prices
(f) Bio-Technology Forward PE average
http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/pedata.html NOTE: 2020 PE values
Total back pain sufferers in the U.S. and Europe, 100 million. BRXTQ biotech and patents have the ability to help these individuals.
From the BRXTQ website:
BioRestorative Therapies Inc was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.
Today, BioRestorative is actively developing programs that aim to dramatically increase the quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes.
More information about BRXTQ:
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The Company offers human and plant stem cell derived cosmetic and skin care products. Its programs relate to the treatment of disc/spine disease and metabolic disorders and include Disc/Spine Program (brtxDISC) and Metabolic Program (ThermoStem). Its curved needle device (CND) is a needle system with a curved inner cannula to allow access to difficult-to-locate regions for the delivery or removal of fluids and other substances. The CND is intended to deliver stem cells and/or other therapeutic products or material to the interior of a human intervertebral disc, the spine region, or other areas of the body. The device relies on the use of pre-curved nested cannulae that allows the cells or material to be deposited in the posterior and lateral aspects of the disc to which direct access is not possible due to outlying structures.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, whether the Company will be able to consummate the private placement and the satisfaction of closing conditions related to the private placement and those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements. The publisher of this article is a current shareholder of BRXTQ. This publication is only intended to share current news from other media outlets about BRXTQ.
Source :BRTXQ Shareholders
This article was originally published by IssueWire. Read the original article here.